You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Determination of optimal antisense oligonucleotide chemistry for efficient and safe splicing modulation in T cells

    SBC: Autoimmunity Biologic Solutions, Inc.            Topic: NIAID

    PROJECT SUMMARY Multiple Sclerosis (MS) is the most common neurological disease of early adulthood and is mediated by autoimmune mechanisms that lead to demyelination and neuronal damage in the central nervous system, resulting in progressive neurological dysfunction. There is no cure for the disease and current treatments focus on preventing future immunological attacks, mainly by suppressing the ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Non-invasive Detection of Cerebral Aneurysm Recurrence after Endovascular Treatment Using Automated Image Processing

    SBC: Medical Innovators Company, LLC            Topic: 101

    PROJECT SUMMARY Hemorrhage due to cerebral aneurysm rupture is a devastating condition with high mortality. For the more than 30,000 patients in the US who are diagnosed annually with an aneurysm, treatment consists of preventing rupture, and increasingly relies of endovascular techniques. However, treatment durability is unknown with recurrence estimated at 16-40% and the re-treatment of 10-20%. ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. An adjuvanted influenza vaccine platform for dose sparing, multiplexing, and rapid deployment

    SBC: POP Biotechnologies Inc.            Topic: NIAID

    Abstract Influenza is the cause of considerable morbidity and mortality globally. Certain groups, i.e., infants, pregnant young women, and older adults are especially at risk for severe disease. Despite immunization being the most effective and economical prophylactic approach, vaccines often provide less than optimal defense against an influenza illness, with efficacies ranging from 10-60%. This ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Application of TNFRSF25 agonists for prophylaxis and treatment of graft versus host disease

    SBC: PELICAN THERAPEUTICS, INC.            Topic: NIAID

    PROJECT SUMMARY Graft-vs-Host-Disease (GVHD) is a frequent and life-threatening complication of hematopoietic stem cell transplantation (HSCT), a procedure that often represents the best treatment option for patients suffering from hematological malignancies. Even when HLA-matched family or unrelated donors are available, an unsatisfactorily high frequency (30-40%) of transplant recipients still d ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Biodegradability and Biocompatibility of a Shape Memory Polymer Wrap to Improve Saphenous Vein Graft Patency in Peripheral and Coronary Artery Bypass Grafting Surgeries

    SBC: VenoStent, Inc.            Topic: NHLBI

    PROJECT SUMMARY/ABSTRACT Peripheral artery disease (PAD) affects nearly 12 million people in the United States. One of the most common surgical therapies is peripheral artery bypass grafting (PABG). Some patients are eligible for less invasive treatment options like angioplasty, but patients with calcified lesions are not. In patients that do receive PABG, approximately 20% fail within the first y ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. A PET Diagnostic for Imaging Bacterial Infection

    SBC: CHRONUS PHARMACEUTICALS, INC.            Topic: NIBIB

    PROJECT SUMMARY Bacterial infections such as those of prosthetic joints, bones (osteomyelitis) and heart valves (infective endocarditis) are difficult to diagnose and treat, and are a major cause of mortality, morbidity and health care costs. The long-term goal of our program is to develop a positron emission tomography (PET) radiotracer that can be used for non-invasive PET imaging to detect and ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Intraoperative Analytics and Enhanced Patient Outcomes

    SBC: M&S Biotics, Inc.            Topic: NCATS

    PROJECT SUMMARY / ABSTRACT Prolonged operative times are associated with significant patient morbidity and mortality, and multiple studies have quantified the degree to which prolonged operative time increases a patientandapos;s risk of adverse complications, like infections. Similarly, ineffective asset management in the OR leads to inefficient utilization of resources and may contribute to prolo ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Chemical-based Nitric Oxide Gas-generating Drug Device for the Treatment of Pulmonary Hypertension

    SBC: Technology Commercialization Partners LLC            Topic: NHLBI

    ABSTRACT Pulmonary hypertension (PH) is a highly debilitating disease that affects about 1% of the global population, which increases up to 10% in individuals aged more than 65 years. The life expectancy for these patients is less than 10 years after diagnosis, and no specific drugs are available for pharmacologic treatment. Despite the introduction PDE5, prostacyclin analogs, and endothelin antag ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Targeted Therapies for the Treatment of GI-ARS Diarrhea

    SBC: RXBIO INC            Topic: 300

    The US population at large, and particularly military personnel and first responders, are at risk of radiation exposure due to the explosion of a nuclear device, a nuclear reactor accident, and the threat of radiation terror- ism. There is no radiation medical countermeasure (RCM) drug approved by the FDA that meets the criterion of a gastrointestinal (GI) radiomitigator – an agent which mitigat ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. CNS Gene Therapy for CLN2 Disease Using Parallel Multiple Routes of Administration

    SBC: LEXEO Therapeutics LLC            Topic: NINDS

    Abstract. In partnership with the Crystal laboratory, Weill Cornell, LEXEO is developing an adeno-associ- ated virus (AAV)-based gene therapy to treat the central nervous system (CNS) manifestations of CLN2 (Batten) disease, a fatal, childhood autosomal recessive neurodegenerative lysosomal storage disorder caused by mutations in the CLN2 gene, coding for a lysosomal enzyme, tripeptidyl peptidase ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government